# iMBIORAY

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/imbioray

- Industry: Biotechnology
- Headquarters: Hangzhou, China
- Total disclosed funding: $36M
- Latest round: Series A (Jan 21, 2025)
- Investors on record: 10

## About

Established in 2014 and based in Hangzhou, China, iMBIORAY (Hangzhou) Biopharmaceutical Co., Ltd., trading under the name iMBIORAY, operates as a medical company that focuses on the research and development of tumor drugs. Zhenwei Miao, the founder and CEO of the company, once served as chief scientist of Enanta and senior chemical director of Ambrx. In February 2026, the firm raised CNY 200 million in series B funding.

The company provides cancer and immune diseases treatment, and tumor cell immunotherapy drug. The company focuses on CAR-NK cell therapy, bispecific antibodies and AIC drugs R&D. The company develops bispecific antibody technology and antibody conjugation (ADC) technology. The company's products include CAR-raNK IBR733 and IBR854, and tiNK cell therapy. Products can be used in tumor immunotherapy, immune diseases, chronic diseases and CNS diseases.

The company’s revenue is generated by the development and potential licensing of immunotherapy drug candidates and cell therapy platforms. It also earns income through strategic research collaborations and partnerships with other pharmaceutical entities to co-develop bispecific antibodies and antibody-drug conjugate (ADC) technologies.

The company plans to use the series B funding to accelerate the clinical development of its core products, expand its large-scale manufacturing capacity, and strengthen its commercial layout.

## Funding rounds

- Series A, Jan 21, 2025 — HY Capital, HRVC Capital, Tailong VC, Sunzi Technology
- Series A, Feb 22, 2022, $36M — South China Venture Capital, Zhuhai Longmen Capital Management, Shenzhen Lucky Source Investment Management, Shenzhen Oriental Huisheng Capital Management, Zhongguancun Kaiyuan Capital, Beiyu Private Equity Fund

## Investors

- South China Venture Capital (https://capitalatlas.ai/funds/south-china-venture-capital) — Series A
- Zhuhai Longmen Capital Management (https://capitalatlas.ai/funds/zhuhai-longmen-capital-management) — Series A
- Shenzhen Lucky Source Investment Management (https://capitalatlas.ai/funds/shenzhen-lucky-source-investment-management) — Series A
- Shenzhen Oriental Huisheng Capital Management — Series A
- Zhongguancun Kaiyuan Capital (https://capitalatlas.ai/funds/zhongguancun-kaiyuan-capital) — Series A
- Beiyu Private Equity Fund — Series A
- HY Capital (https://capitalatlas.ai/funds/hy-capital) — Series A
- HRVC Capital (https://capitalatlas.ai/funds/hrvc-capital) — Series A
- Tailong VC (https://capitalatlas.ai/funds/tailong-vc) — Series A
- Sunzi Technology — Series A